Literature DB >> 9010054

Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ.

D Mulherin1, O Fitzgerald, B Bresnihan.   

Abstract

The contrast between clinical improvement and radiological deterioration in rheumatoid arthritis (RA) is striking. We characterized this relationship using serial disease activity measures and radiographs of hands and feet in 40 RA patients observed over 6 yr. All disease activity measures improved, including grip strength, Ritchie index (RI), haemoglobin and erythrocyte sedimentation rate (ESR) (all P < 0.0001). In contrast, articular erosion increased (P < 0.0001). Radiological change during the study correlated with RI (r = 0.49), haemoglobin (r = -0.56) and ESR (r = 0.53). Radiological status at review also correlated with these variables (r = 0.36, -0.44 and 0.36, respectively). Articular erosion continues in RA despite clinical improvement and is accelerated in those with evidence of continuing synovial inflammation, reflected in clinical and laboratory measures of disease activity. Since many therapies in RA suppress inflammation, but not erosion, these findings suggest that the pathogenesis of articular erosion may differ from that of synovial inflammation.

Entities:  

Mesh:

Year:  1996        PMID: 9010054     DOI: 10.1093/rheumatology/35.12.1263

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  44 in total

1.  Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys.

Authors:  H P Brok; J M Tekoppele; J Hakimi; J A Kerwin; E M Nijenhuis; C W De Groot; R E Bontrop; B A 't Hart
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 2.  Interpreting radiographic data in rheumatoid arthritis.

Authors:  P A Ory
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

3.  The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

4.  Patients with rheumatoid arthritis in clinical care.

Authors:  J S Smolen; D Aletaha
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

Review 5.  Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities.

Authors:  C P Chung; J L Thompson; G G Koch; I Amara; V Strand; T Pincus
Journal:  Ann Rheum Dis       Date:  2006-02-27       Impact factor: 19.103

Review 6.  [Expression analyses for rheumatoid arthritis].

Authors:  R Guenther; V Krenn; T Häupl
Journal:  Z Rheumatol       Date:  2008-02       Impact factor: 1.372

7.  T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis.

Authors:  M C Kraan; J J Haringman; H Weedon; E C Barg; M D Smith; M J Ahern; T J M Smeets; F C Breedveld; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

8.  The arthritis severity locus Cia5d is a novel genetic regulator of the invasive properties of synovial fibroblasts.

Authors:  Teresina Laragione; Max Brenner; Adriana Mello; Marc Symons; Pércio S Gulko
Journal:  Arthritis Rheum       Date:  2008-08

Review 9.  Using ultrasonography to facilitate best practice in diagnosis and management of RA.

Authors:  Andrew K Brown
Journal:  Nat Rev Rheumatol       Date:  2009-11-10       Impact factor: 20.543

10.  Power Doppler sonography in the assessment of synovial tissue of the knee joint in rheumatoid arthritis: a preliminary experience.

Authors:  M Carotti; F Salaffi; P Manganelli; D Salera; B Simonetti; W Grassi
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.